Drugs in preclinical to phase II clinical development for the treatment of erectile dysfunction

References

• Sanchez-Cruz JJ, Cabrera-Leon A, Martin-Morales A, et al. Male erectile dysfunction and health-related quality of life. Eur Urol. 2003;44:245–253.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol. 1994;151:54–61.
   PubMed Web of Science ®Google Scholar
• Laumann EO, Paik A, Rosen RC. The epidemiology of erectile dysfunction: results from the national health and social life survey. Int J Impot Res. 1999;11(Suppl 1):S60–4.
   Google Scholar
• Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7:1598–1607.
   PubMed Web of Science ®Google Scholar
• McCabe MP, Sharlip ID, Lewis R, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the fourth international consultation on sexual medicine 2015. J Sex Med. 2016;13:153–167.
   PubMed Web of Science ®Google Scholar
• Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174:230–239.
   PubMed Web of Science ®Google Scholar
• Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47–52.
   PubMedGoogle Scholar
• Evans JD, Hill SR. A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient Prefer Adherence. 2015;9:1159–1164.
   PubMed Web of Science ®Google Scholar
• Peak TC, Yafi FA, Sangkum P, et al. Emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2015;20:263–275.
   PubMed Web of Science ®Google Scholar
• Carvalheira AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9:2361–2369.
   PubMed Web of Science ®Google Scholar
• Coombs PG, Heck M, Guhring P, et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110:1787–1791.
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008;102:933–937.
   PubMed Web of Science ®Google Scholar
• Sung HH, Ahn JS, Kim JJ, et al. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. Andrology. 2014;2:45–50.
   PubMed Web of Science ®Google Scholar
• Gomez MV, Kalapothakis E, Guatimosim C, et al. Phoneutria nigriventer venom: a cocktail of toxins that affect ion channels. Cell Mol Neurobiol. 2002;22:579–588.
   PubMed Web of Science ®Google Scholar
• Jung AR, Choi YS, Piao S, et al. The effect of PnTx2-6 protein from phoneutria nigriventer spider toxin on improvement of erectile dysfunction in a rat model of cavernous nerve injury. Urology. 2014;84:730.e9–730.17.
   Web of Science ®Google Scholar
• d’Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, et al. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci USA. 2009;106:4513–4518.
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Sikka SC, et al. Overview of potential molecular targets for hydrogen sulfide: a new strategy for treating erectile dysfunction. Nitric Oxide. 2015;50:65–78.
   PubMed Web of Science ®Google Scholar
• Jupiter RC, Yoo D, Pankey EA, et al. Analysis of erectile responses to H2S donors in the anesthetized rat. Am J Physiol Heart Circ Physiol. 2015;309:H835–43.
   Google Scholar
• Albersen M, Linsen L, Tinel H, et al. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013;10:1268–1277.
   PubMed Web of Science ®Google Scholar
• Chen J, Wollman Y, Chernichovsky T, et al. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. 1999;83:269–273.
   PubMed Web of Science ®Google Scholar
• Neuzillet Y, Hupertan V, Cour F, et al. A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. Andrology. 2013;1:223–228.
   PubMed Web of Science ®Google Scholar
• Stanislavov R, Nikolova V, Rohdewald P. Improvement of erectile function with prelox: a randomized, double-blind, placebo-controlled, crossover trial. Int J Impot Res. 2008;20:173–180.
   PubMed Web of Science ®Google Scholar
• Alwaal A, Zaid UB, Lin CS, et al. Stem cell treatment of erectile dysfunction. Adv Drug Deliv Rev. 2015;82–83;137–144.
   PubMed Web of Science ®Google Scholar
• Hakim L, Van der Aa F, Bivalacqua TJ, et al. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol. 2012;9:520–536.
   PubMed Web of Science ®Google Scholar
• Jin HR, Kim WJ, Song JS, et al. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. J Sex Med. 2010;7:3635–3646.
   PubMed Web of Science ®Google Scholar
• Condorelli RA, Calogero AE, Vicari E, et al. Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches. Andrology. 2013;1:533–540.
   PubMed Web of Science ®Google Scholar
• Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol. 2003;169:1577–1581.
   PubMed Web of Science ®Google Scholar
• Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res. 2003;15:26–37.
   PubMed Web of Science ®Google Scholar
• Camargo PM, Lekovic V, Weinlaender M, et al. Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. J Periodontal Res. 2002;37:300–306.
   PubMed Web of Science ®Google Scholar
• Ding XG, Li SW, Zheng XM, et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl. 2009;11:215–221.
   PubMed Web of Science ®Google Scholar
• Wu YN, Wu CC, Sheu MT, et al. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016;10:E294–E304.
   PubMed Web of Science ®Google Scholar
• Araki T, Milbrandt J. Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. Neuron. 1996;17:353–361.
   PubMed Web of Science ®Google Scholar
• Yin GN, Choi MJ, Kim WJ, et al. Inhibition of ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse. Proc Natl Acad Sci USA. 2014;111:E2731–40.
   PubMed Web of Science ®Google Scholar
• Hawksworth DJ, Burnett AL. Pharmacotherapeutic management of erectile dysfunction. Clin Pharmacol Ther. 2015;98:602–610.
   PubMed Web of Science ®Google Scholar
• Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int J Impot Res. 2000;12(Suppl 4):S74–9.
   PubMed Web of Science ®Google Scholar
• Lansdell MI, Hepworth D, Calabrese A, et al. Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. J Med Chem. 2010;53:3183–3197.
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16:51–59.
   PubMed Web of Science ®Google Scholar
• Albersen M, Shindel AW, Mwamukonda KB, et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerg Drugs. 2010;15:467–480.
   PubMed Web of Science ®Google Scholar
• Burnett AL. Erectile dysfunction management for the future. J Androl. 2009;30:391–396.
   PubMedGoogle Scholar
• Ryu JK, Choi MJ, Kim TI, et al. A guanidinylated bioreducible polymer as a novel gene carrier to the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. Andrology. 2013;1:216–222.
   PubMed Web of Science ®Google Scholar
• Song KM, Choi MJ, Kwon MH, et al. Optimizing in vivo gene transfer into mouse corpus cavernosum by use of surface electroporation. Korean J Urol. 2015;56:197–204.
   PubMedGoogle Scholar
• Yoshimura N, Kato R, Chencellor MB, et al. Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther. 2010 Sep;10(9):1305–1314.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Strong TD, Gebska MA, et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol. 2010;184:2197–2204.
   PubMed Web of Science ®Google Scholar
• Song SH, Park K, Kim SW, et al. Involvement of rho-Kinase/LIM Kinase/Cofilin signaling pathway in corporal fibrosis after cavernous nerve injury in male rats. J Sex Med. 2015;12:1522–1532.
   PubMed Web of Science ®Google Scholar
• Liu GY, Jiang XX, Zhu X, et al. ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro. Acta Pharmacol Sin. 2015;36:1473–1479.
   PubMed Web of Science ®Google Scholar
• Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165–1176.
   PubMed Web of Science ®Google Scholar
• Soebadi MA, Moris L, Castiglione F, et al. Advances in stem cell research for the treatment of male sexual dysfunctions. Curr Opin Urol. 2016;26:129–139.
   PubMed Web of Science ®Google Scholar
• Li M, Li H, Ruan Y, et al. Stem cell therapy for diabetic erectile dysfunction in rats: a meta-analysis. PLoS One. 2016;11:e0154341.
   PubMed Web of Science ®Google Scholar
• Yang R, Fang F, Wang J, et al. Adipose-derived stem cells ameliorate erectile dysfunction after cavernous nerve cryoinjury. Andrology. 2015;3:694–701.
   PubMed Web of Science ®Google Scholar
• Qiu X, Fandel TM, Ferretti L, et al. Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury. Eur Urol. 2012;62:720–727.
   PubMed Web of Science ®Google Scholar
• Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBio Medicine. 2016;5:204–210.
   PubMed Web of Science ®Google Scholar